Domača stranGLAXF • OTCMKTS
add
GSK plc
Prejšnji trg. dan.
18,06 $
Letni razpon
16,80 $ - 23,00 $
Tržna kapitalizacija
75,06 mrd. USD
Povprečni obseg
2,06 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
LON
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (GBP) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 8,01 mrd. | −1,66 % |
Stroški poslovanja | 5,02 mrd. | 59,83 % |
Čisti dohodek | −58,00 mio. | −103,96 % |
Čista dobičkovnost prihodkov | −0,72 | −104,01 % |
Earnings per share | 1,29 | 5,78 % |
EBITDA | 1,62 mrd. | −51,61 % |
Efektivna davčna stopnja | −1,56 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (GBP) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 3,21 mrd. | −51,94 % |
Skupna sredstva | 58,05 mrd. | −4,62 % |
Skupne obveznosti | 44,60 mrd. | −7,56 % |
Celoten lastniški kapital | 13,45 mrd. | — |
Shares outstanding | 4,08 mrd. | — |
Razmerje P/B | 5,27 | — |
Donosnost sredstev | 2,87 % | — |
Donosnost kapitala | 5,54 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (GBP) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −58,00 mio. | −103,96 % |
Denar iz dejavnosti | 2,15 mrd. | −2,62 % |
Denar iz naložb | −731,00 mio. | −48,88 % |
Denar iz financiranja | −1,24 mrd. | 29,63 % |
Neto sprememba denarnih sredstev | 149,00 mio. | 927,78 % |
Prost denarni tok | 1,89 mrd. | 40,47 % |
Vizitka
GSK plc is a British multinational pharmaceutical and biotechnology company with headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
GSK is the tenth largest pharmaceutical company and No. 294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it had a market capitalisation of £69 billion, the eighth largest on the London Stock Exchange.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Legacy products developed at GSK include several listed in the World Health Organization's List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine and zidovudine. Wikipedia
Generalni direktor
Datum ustanovitve
27. dec. 2000
Spletno mesto
Zaposleni
70.212
